Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 13/02/2025			5-day change	1st Jan Change
177,900.00 ^KRW	-0.45%		-1.71%	-5.12%

02-11	S.Korean shares end at 3-week high on tariff optimism despite Trump's comments	RE
02-11	South Korean shares rise 1% on tariff optimism despite Trump's comments	RE

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 25, 2024.

November 20, 2024 at 10:31 pm

From October 25, 2024 to November 19, 2024, the company has repurchased 537,924 shares, representing 0.26% for KRW 94,709.84 million. With this, the company has completed the repurchase of 537,924 shares, representing 0.26% for KRW 94,709.84 million under the buyback announced on October 25, 2024.

Latest news about Celltrion, Inc.

S.Korean shares end at 3-week high on tariff optimism despite Trump's comments	02-11	RE
South Korean shares rise 1% on tariff optimism despite Trump's comments	02-11	RE
South Korean Shares Rally on US Tariff Delay; Celltrion Shares Rise 1% on FDA Approval for ACTEMRA Biosimilar	02-04	MT
Celltrion Secures FDA Approval for AVTOZMA Tocilizumab Biosimilar	02-04	MT
Celltrion Launches SteQeyma Across Five European Countries	01-24	MT
Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline At the 43Rd Annual J.P. Morgan Healthcare Conference	01-15	CI
Celltrion to Unveil Drug Development Plans at JP Morgan Conference	01-09	MT
Celltrion, Inc. announces an Equity Buyback for 546,747 shares.	12-27	CI
Celltrion, Inc. authorizes a Buyback Plan.	12-26	CI
Bargain-Hunting Amid Martial-Law-Attempt-led Political Turmoil Leads South Korean Shares Higher	12-18	MT
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on November 21, 2024.	12-18	CI
U.S. FDA Approves Celltrion's STEQEYMA® (Ustekinumab-Stba), a Biosimilar to Stelara® (ustekinumab)	12-18	CI
Celltrion Establishes New Subsidiary Celltrion BioSolutions	12-18	MT
South Korean Markets Decline as Investors Book Profits Amid Acting President Step-In	12-16	MT
European Medicines Agency's Human Use Committee Backs Approval for Celltrion Biosimilars	12-16	MT
South Korean Shares Rebound on Market Stabilization Optimism; Celltrion Gains 4% on Asthma Drug's Canada Approval	12-10	MT
Health Canada Approves Celltrion's Asthma Biosimilar Omlyclo; Shares Rise 3%	12-10	MT
Health Canada Approves Celltrion?s Omlyclo (CT-P39), the First and Only Omalizumab Biosimilar in Canada	12-10	CI
Celltrion Begins Commercial Operation of Third Domestic Manufacturing Plant; Shares Jump 4%	12-10	MT
Celltrion to Retire 3 Million Treasury Stock in January	12-05	MT
South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	12-04	MT
BioMe Inc. announced that it expects to receive funding from Celltrion, Inc.	12-02	CI
Celltrion, Inc. - Analyst/Investor Day	11-27
Celltrion Launches KRW100 Billion Share Buyback	11-22	MT
Celltrion, Inc. announces an Equity Buyback for 583,431 shares.	11-20	CI

Chart Celltrion, Inc.

Duration

Period

A068270: Dynamic Chart

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,391

Sector

Biotechnology & Medical Research

Calendar

06/04/2025 - Q4 2024 Earnings Release (Projected)

More about the company